Editas Medicine, Inc.

EDIT · Nasdaq · ·

비교

US$2.38-4.8%11월 11일 종가

2026년 9월 30일까지의 수치 (2026년 11월 9일 제출 10-Q 기준)

1W: -7.4%
1M: -2.7%
3M

Editas Medicine, Inc. (EDIT) 주식 — 좋은 사업일까? — InspectStocks

Editas Medicine, Inc.

EDIT · Nasdaq · ·

비교

US$2.38-4.8%11월 11일 종가

2026년 9월 30일까지의 수치 (2026년 11월 9일 제출 10-Q 기준)

1W: -7.4%
1M: -2.7%
3M

Just reported

Q3 2026 results

From Editas Medicine's results release of 2026년 11월 9일; its quarterly report has since been filed.

Revenue
Actual
US$10.4M
+37% y/y
-13% q/q
Guided
—
No guide given
EPS, GAAP
Actual
-US$0.15
Guided
—
No guide given
Operating income, GAAP
Actual
-US$24.3M
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Editas Medicine is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

어떻게 돈을 버는가

Licensing and research collaborations100%

매출 비중은 FY2025 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.

경쟁 상대

무엇을 파는가3

EDIT-401
An experimental one-time treatment designed to edit liver cells so they produce more of a protein that removes LDL cholesterol from the blood. It was being prepared for a Phase 1/2 human trial in people with inherited high cholesterol.
In-vivo blood stem-cell editing program
A research program intended to edit blood-forming stem cells inside the body to raise fetal hemoglobin, with the aim of treating sickle cell disease and transfusion-dependent beta thalassemia.
Cas9 and Cas12a gene-editing technology
Gene-editing tools that Editas licenses to partners for research and development of medicines, including treatments that modify immune cells.

누가 사는가3

Bristol Myers Squibb: collaborates on research into gene-edited immune-cell treatments and may make milestone and royalty payments.
Vertex Pharmaceuticals: licenses Editas gene-editing technology for medicines targeting inherited blood disorders and pays annual license fees.
Immatics: collaborates with Editas on gene-edited immune-cell treatments for cancer.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1The business depends heavily on EDIT-401, its lead medicine, and on advancing it from preclinical research into human trials.
2Editas licenses important gene-editing patents from universities and research institutions; those agreements require payments and compliance with their terms.
3It relies on outside manufacturers and service providers for research materials and planned clinical trials, and on partners and investors for funding.

잘못될 수 있는 일

1EDIT-401 has not yet established safety or effectiveness in people; failure or delay in its development could significantly affect the business.
2Gene-editing patents and licenses are subject to disputes and challenges, which could limit Editas's rights to use or license important technology.
3Editas has no medicine-sale revenue and needs substantial funding; if it cannot raise money or receive partner payments, it may have to cut or delay research and development.

전체 재무제표 보기 →